The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis

被引：2
|
作者：
Bordbar, Mohammadreza [1 ]
Hosseini-Bensenjan, Mahnaz [1 ]
Sayadi, Mehrab [2 ]
Zekavat, Omidreza [1 ]
Bordbar, Shayan [3 ]
Nozari, Farnoosh [1 ]
Haghpanah, Sezaneh [1 ]
机构：
[1] Shiraz Univ Med Sci, Hematol Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Cardiovasc Res Ctr, Shiraz, Iran
[3] Shiraz Univ Med Sci, Student Res Ctr, Shiraz, Iran
来源：
CANCER INVESTIGATION | 2024年 / 42卷 / 06期
关键词：
Acute myeloid leukemia; granulocyte colony-stimulating factor; relapse; survival; meta-analysis; COLONY-STIMULATING FACTOR; HEMATOPOIETIC GROWTH-FACTORS; ACUTE MYELOGENOUS LEUKEMIA; PLACEBO-CONTROLLED TRIAL; INDUCTION CHEMOTHERAPY; FEBRILE NEUTROPENIA; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; DOUBLE-BLIND; CELL-CYCLE;
D O I：
10.1080/07357907.2024.2352454
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.
引用
收藏
页码：452 / 468
页数：17
相关论文
共 50 条
  • [1] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Wei, Guoqing
    Ni, Wanmao
    Chiao, Jen-wei
    Cai, Zhen
    Huang, He
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [2] Use of Primary Prophylaxis with G-CSF in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy Does Not Affect Quality of Response
    Mezzanotte, Valeria
    Paterno, Giovangiacinto
    Cerroni, Ilaria
    De Marchi, Lucrezia
    Taka, Kristian
    Buzzatti, Elisa
    Mallegni, Flavia
    Meddi, Elisa
    Moretti, Federico
    Buccisano, Francesco
    Maurillo, Luca
    Palmieri, Raffaele
    Gurnari, Carmelo
    Venditti, Adriano
    Del Principe, Maria Ilaria
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [3] Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
    Maeda, Tomoya
    Najima, Yuho
    Kamiyama, Yutaro
    Nakao, Shinji
    Ozaki, Yukinori
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Ichihara, Eiki
    Miumra, Yuji
    Endo, Makoto
    Maruyama, Dai
    Yoshinami, Tatsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Yano, Shingo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 535 - 544
  • [4] Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years
    Sperr, Wolfgang R.
    Herndlhofer, Susanne
    Gleixner, Karoline
    Girschikofsky, Michael
    Weltermann, Ansgar
    Machherndl-Spandl, Sigrid
    Sliwa, Thamer
    Poehnl, Rainer
    Buxhofer-Ausch, Veronika
    Strecker, Karin
    Hoermann, Gregor
    Knoebl, Paul
    Jaeger, Ulrich
    Geissler, Klaus
    Kundi, Michael
    Valent, Peter
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : E567 - E574
  • [5] Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis
    Li, Xiang
    Zheng, Huan
    Yu, Man-Cheng
    Wang, Wei
    Wu, Xin-Hong
    Yang, Dong-Mei
    Xu, Juan
    SUPPORTIVE CARE IN CANCER, 2020, 28 (11) : 5085 - 5097
  • [6] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Guoqing Wei
    Wanmao Ni
    Jen-wei Chiao
    Zhen Cai
    He Huang
    Delong Liu
    Journal of Hematology & Oncology, 4
  • [7] Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis
    Feng, Xiaoqin
    Lan, He
    Ruan, Yongsheng
    Li, Chunfu
    HEMATOLOGY, 2018, 23 (09) : 581 - 589
  • [8] The Effect of Using Prophylactic G-CSF during Chemotherapy on the Outcome of Children with Acute Lymphoblastic Leukemia
    Abdollahpour, Marjan
    Salajegheh, Pourya
    Bahoush, Gholamreza
    ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2021, 11 (03) : 1318 - 1323
  • [9] G-CSF IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA - IS IT SAFE
    OHNO, R
    LEUKEMIA & LYMPHOMA, 1993, 11 : 15 - 19
  • [10] Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
    Ozaki, Yukinori
    Yokoe, Takamichi
    Yoshinami, Tetsuhiro
    Nozawa, Kazuki
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Ichihara, Eiki
    Miura, Yuji
    Endo, Makoto
    Yano, Shingo
    Maruyama, Dai
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Kamiyama, Yutaro
    Nakao, Shinji
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (5) : 551 - 558
12345